1123231-07-1
1123231-07-1
Chemical Structure
WAY-262611
- CAS No.: 1123231-07-1
- Formula:C20H22N4
- Molecular Weight:318.42
IUPAC Name: (1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine
InChIKey: QHLITPHIARVDJI-UHFFFAOYSA-N
SMILES: NCC1CCN(C2=NC=CC(C3=CC=C4C=CC=CC4=C3)=N2)CC1
Biological Activity: WAY-262611 is a Wnt/β-Catenin agonist that increases bone formation rate with an EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also a Dkk1 inhibitor[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
WAY-262611 | 99.96% | WAY-262611 is a Wnt/β-Catenin agonist that increases bone formation rate with an EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also a Dkk1 inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
WAY-262611 (Standard) | ≥98% | WAY-262611 (Standard) is the analytical standard of WAY-262611 (HY-11035). This product is intended for research and analytical applications. WAY-262611 is a Wnt/β-Catenin agonist that increases bone formation rate with an EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also a Dkk1 inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
T808 | 98.20% | T808 is a selective tau protein-targeting ligand. T808 can be used to synthesize [18F]-T808, a highly selective tau protein positron emission tomography (PET) tracer. T808 can also be used to synthesize [3H]-T808, a marker for in vitro experiments. T808 can be used for the research of alzheimer’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Perafensine | Perafensine (HR 459) is an antidepressant agent. Perafensine has cytochrome P450-inducing properties. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LX-6171 | 97.09% | LX-6171 is an orally active SLC6A7 inhibitor. LX-6171 can be used to study diseases characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AP-C5 | 99.30% | AP-C5 displays selective inhibition of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 7.2, which can be used for the research of diarrheal disease. AP-C5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AP-C1 | AP-C1 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC50 of 6.5. AP-C1 only weakly inhibits cGKII-dependent anion secretion. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Skp2 inhibitor 2 | 99.88% | Skp2 inhibitor 2 is a Skp2-Cks1 protein-protein interaction inhibitor with a human IC50 of 0.57 μM. Skp2 inhibitor 2 binds to Skp2 at the interaction interface to block Skp2-Cks1 complex formation. Skp2 inhibitor 2 can be used for the research of gastric cancer, non-small cell lung cancer, breast cancer, prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
JAK1/2 ligand 1 | 99.91% | JAK1/2 ligand 1 is a ligand for the PROTAC target protein of JAK1/2, which can be used to synthesize PROTAC JAK1/2 degrader-1 (HY-179715). JAK1/2 ligand 1 is applicable to the research of colitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ADORA1 modulator-1 | ADORA1 modulator-1 is an ADORA1 modulator. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Anticancer agent 299 | Anticancer agent 299 (compound P12) is a cell-cycle inhibitor, senescence inducer, apoptosis inducer, and antiproliferative agent. Anticancer agent 299 exhibits selective activity against cancer cells with minimal effects on non-tumoral chondrocyte cells at relevant concentrations. Anticancer agent 299 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CaMKII-IN-4 | CaMKII-IN-4 is a pyrimidine-based ATP-competitive CaMKIIδ inhibitor with an enzymatic IC50 of >20 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
